Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") on September 12, 2016, regarding events occurring on September 8, 2016. The filing details the entry into a material definitive agreement for equity financing and the resignation of a director.
Key Financial Metrics and Transaction Details
- Financing Facility: Entered into a $15 million common stock purchase agreement with Aspire Capital Fund, LLC.
- Initial Proceeds: Received $1 million from the sale of 250,000 shares at $4.00 per share.
- Commitment Fee: Issued 175,000 shares of common stock as a commitment fee to Aspire Capital.
- Term: The agreement allows for purchases over a 30-month period.
- Use of Proceeds: Funds are designated for research and development, working capital, and general corporate purposes.
- Financial Covenants: The filing states there are no financial or business covenants, restrictions on future financings, or penalties in the agreement.
Material Changes and Corporate Actions
- Equity Issuance: Immediate issuance of 425,000 shares (250,000 Initial Shares + 175,000 Commitment Shares) on September 8, 2016.
- Board Resignation: Behshad Sheldon resigned from the Board of Directors, effective September 30, 2016.
- Registration Rights: Executed a registration rights agreement to register the Initial Shares, Commitment Shares, and future shares issuable under the purchase agreement.
Outlook, Risks, and Unusual Items
- Pricing Mechanism: Future share prices are determined by the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding ten business days. A "VWAP Purchase Notice" option exists if the closing price exceeds $0.50.
- Termination Rights: Cerecor may terminate the agreement at any time for any reason without liability. Aspire Capital may terminate only upon an event of default.
- Short-Selling Restrictions: Aspire Capital is prohibited from short-selling or hedging the common stock during the term of the agreement.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from projections.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-issuance to assess dilution impact.
- Confirm the status of the Registration Statement required to sell the shares publicly.
- Review the company's cash runway and specific R&D milestones to be funded by the $15 million facility.
- Monitor the stock price relative to the $0.50 floor price which restricts sales under the agreement.
- Check for any subsequent filings regarding the replacement of the resigned director, Behshad Sheldon.